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In response to DNA damage, p53 undergoes post-translational modifications (including acetylation) that are
critical for its transcriptional activity. However, the mechanism by which p53 acetylation is regulated is still
unclear. Here, we describe an essential role for HLA-B-associated transcript 3 (Bat3)/Scythe in controlling the
acetylation of p53 required for DNA damage responses. Depletion of Bat3 from human and mouse cells
markedly impairs p53-mediated transactivation of its target genes Puma and p21. Although DNA
damage-induced phosphorylation, stabilization, and nuclear accumulation of p53 are not significantly affected
by Bat3 depletion, p53 acetylation is almost completely abolished. Bat3 forms a complex with p300, and an
increased amount of Bat3 enhances the recruitment of p53 to p300 and facilitates subsequent p53 acetylation.
In contrast, Bat3-depleted cells show reduced p53–p300 complex formation and decreased p53 acetylation.
Furthermore, consistent with our in vitro findings, thymocytes from Bat3-deficient mice exhibit reduced
induction of puma and p21, and are resistant to DNA damage-induced apoptosis in vivo. Our data indicate
that Bat3 is a novel and essential regulator of p53-mediated responses to genotoxic stress, and that Bat3
controls DNA damage-induced acetylation of p53.
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Bat3 (HLA-B-associated transcript 3) was originally iden-
tified as a gene within the class III region of the human
major histocompatibility complex on chromosome 6
(Spies et al. 1989; Banerji et al. 1990). The biological
function of Bat3 is currently unknown. The Xenopus ho-
molog of Bat3, Scythe, was recently shown to interact
with Reaper (Rpr), a crucial regulator of apoptosis in Dro-
sophila melanogaster (Thress et al. 1998). The Rpr–
Scythe interaction is essential for Rpr-induced apoptosis
in a Xenopus egg cell-free system and results in features
typical of apoptosis, such as mitochondrial cytochrome c
release, caspase activation, and nuclear fragmentation
(Thress et al. 1999). Structurally, Bat3/Scythe contains
an N-terminal ubiquitin homology region, short tracts of
polyproline and polyglycine, and a zinc finger-like do-
main; however, the functional implications of these do-
mains are unknown (Banerji et al. 1990). Bat3/Scythe
also contains a nuclear localization signal (NLS) at its C
terminus (CT) (Manchen and Hubberstey 2001). How-
ever, a recent report has shown that the majority of en-
dogenous Bat3 can be found in the cytosolic fraction in
multiple mouse primary tissues (Kislinger et al. 2006).
Certain sequence domains in Bat3/Scythe also appear in
the BAG family of proteins that negatively regulate the
chaperone function of the Hsp70 family. Thus, Bat3/
Scythe may be important for the folding and activity of
signaling molecules regulating apoptosis (Thress et al.
2001). Bat3-deficient mice are embryonic lethal with de-
fects in the development of the brain, lung, and kidney
(Desmots et al. 2005), and primary neuronal cells defi-
cient for Bat3 are resistant to in vitro apoptosis induced
by calcium overloading in the endoplasmic reticulum
(ER) (Desmots et al. 2005). Taken together, these data
suggest that Bat3 may regulate both proliferation and
cell death.
The tumor suppressor protein p53 is a key guardian of
genomic stability (Lane 1992). In response to a variety of
cellular stresses, p53 governs critical cell fate decisions
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resulting in cell cycle arrest, DNA repair, senescence, or
apoptosis (Levine 1997; Vogelstein et al. 2000; Vousden
and Lu 2002). The ability of p53 to inhibit the cell cycle
or promote apoptosis depends largely on p53’s ability to
control the transcription of target genes regulating cell
proliferation and apoptosis. Such genes include p21/
WAF1, Gadd45, Noxa, Puma, Bax, p53AIP1, and survivin
(Levine 1997; Prives and Hall 1999; Hoffman et al. 2002;
Vousden and Lu 2002). The importance of p53’s tran-
scriptional activity to its tumor suppressor function is
underscored by the fact that >97% of mutations in hu-
man cancers are located within the p53 DNA-binding
domain (Olivier et al. 2002).
In healthy cells, p53 is maintained at a low level
through interaction with proteins such as Mdm2/Hdm2
(human Mdm2) (Iwakuma and Lozano 2003), COP1 (Dor-
nan et al. 2004), Pirh2 (Leng et al. 2003), and ARF-BP1
(Chen et al. 2005) because these molecules promote
ubiquitination and proteasome-mediated degradation of
p53 (Haupt et al. 1997; Honda et al. 1997; Kubbutat et al.
1997). In response to stress, p53 becomes stabilized
through post-translational modifications, including
phosphorylation and acetylation (Appella and Anderson
2001; Brooks and Gu 2003), and performs its biological
functions. DNA damage-induced phosphorylation by
ATM, Chk2, DNA-PK, or ATR of serine and threonine
residues within the p53 N terminus prevents Mdm2
binding and subsequent ubiquitin-mediated degradation
of p53 (Shieh et al. 1997; Tibbetts et al. 1999; Hirao et al.
2000). Acetylation of the CT of p53 is carried out by
histone acetyltransferases (HATs) such as p300/CREB-
binding protein (CBP) and p300/CBP-associated factor
(PCAF) (Gu and Roeder 1997; Sakaguchi et al. 1998). In
addition to stabilizing p53 by diverting it from Mdm2-
mediated ubiquitination (Li et al. 2002), there is some
evidence that acetylation of p53 regulates its sequence-
specific DNA binding and enhances its transcriptional
activity (Gu and Roeder 1997; Sakaguchi et al. 1998; Luo
et al. 2004), although controversy still exists (Espinosa
and Emerson 2001). Others have reported that p53 acety-
lation promotes transcription by facilitating the recruit-
ment of cofactors to the promoters of p53-responsive
genes (Avantaggiati et al. 1997; Gu and Roeder 1997; Lill
et al. 1997; Ito et al. 1999; Barlev et al. 2001; Espinosa
and Emerson 2001). The complex and dynamic patterns
of post-translational p53 modifications have made this
issue difficult to resolve. An understanding of how p53
acetylation is regulated will be essential for defining its
precise biological function.
In this study, we have identified a critical requirement
for Bat3 in regulating p53 transcriptional activity.
Ablation of Bat3 results in reduced apoptosis in response
to genotoxic stress. In the absence of Bat3, p300 can-
not bind to p53, and p300-mediated acetylation of
p53 is almost completely abolished. Consequently, the
induction of p53 target genes such as p21 and Puma is
severely impaired. Our results demonstrate that Bat3
modulates p300-mediated p53 acetylation and thus func-
tions as a novel regulator of the genotoxic stress re-
sponse.
Results
Bat3 is necessary for DNA damage-induced apoptosis
Because homologs of Bat3 have been implicated in apop-
totic regulation in other organisms, we determined
whether Bat3 deficiency affected the in vitro apoptosis of
mammalian cells using “knockdown” (KD) technology.
Two independent small interfering RNA (siRNA) oligo-
duplexes specific for human Bat3 (siBat3-1 and siBat3-2)
and a control (siCNT) were introduced into the human
osteosacroma cell line U2OS to verify their efficiency.
After 48 h, the level of Bat3 protein was reduced to <10%
of the control in U2OS cells transfected with siBat3-1 or
Bat3-2, whereas introduction of siCNT had no effect on
Bat3 protein levels (Fig. 1A). We then transfected siBat3
and siCNT into U2OS cells and induced apoptosis 72 h
later by treating the cells with staurosporine (STS; 0,
0.01, 0.03, or 0.1 µM) or UV (0, 10, 30, or 100 mJ/cm2). At
16 h post-treatment, annexin V-FITC/PI staining showed
that STS treatment induced apoptosis in siCNT-, siBat3-
Figure 1. Bat3 is necessary for DNA damage response. (A) Ef-
ficient Bat3 KD by siRNA oligo-duplexes. U2OS cells were
transfected with control (siCNT) or Bat3 (siBat3-1 and siBat3-2)
RNA oligo-duplexes, and Bat3 protein levels were assessed 48 h
later by immunoblotting. (actin) Loading control. (B,C) Reduced
DNA damage-induced apoptosis. The cells in A were treated
with staurosporine (STS) (B) or UV (C) as indicated. Percentage
of cell viability was assayed at 16 h post-treatment by an-
nexin-V staining. Data shown are one trial representative of four
independent experiments.
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1-, and siBat3-2-transfected cells to the same extent (Fig.
1B). In contrast, there was a 10%–20% reduction in UV-
induced apoptosis in siBat3-1- and siBat3-2-transfected
cells compared with siCNT-transfected cells (Fig. 1C).
These data suggest that Bat3 plays a regulatory role in
DNA damage-induced apoptosis.
Bat3 is required for p53 transcriptional activity
Given the central role played by p53 in DNA damage-
induced apoptosis, we next investigated the relationship
between Bat3 and the p53 signaling pathway. We first
examined the protein levels of p53 and its transcriptional
target genes in doxorubicin (Dox)-treated U2OS (p53
wild-type) and SaOS2 (p53-null) cells that were trans-
fected with siCNT or siBat3-1. In U2OS cells transfected
with siCNT or siBat3-1, p53 was stabilized such that its
protein levels were increased (Fig. 2A, left). However,
among the p53 target genes tested, the induction of the
p21 and Puma proteins was markedly impaired in siBat3-
transfected U2OS cells compared with the normal induc-
tion observed in siCNT-transfected U2OS cells (Fig. 2A,
left). In contrast, protein levels of the p53 target gene
Hdm2 and Bax were comparable in siCNT- and siBat3-
transfected U2OS cells (Fig. 2A, left). The induction of
p21, Puma, and Hdm2 proteins observed in U2OS cells
was p53-dependent since no induction of these proteins
was observed in siCNT- or siBat3-transfected SaOS2
cells (Fig. 2A, right). We confirmed this finding in an-
other set of cell lines, p53 wild-type and p53-null
HCT116 cells (Bunz et al. 1998). We depleted Bat3 and
treated the cells with Dox. The induction of p21 and
Puma was severely impaired in HCT116 cells depleted
for Bat3 in a p53-dependent manner (Fig. 2B). The protein
levels of Hdm2 and Bax were comparable in siCNT- and
siBat3-transfected HCT116 cells (Fig. 2B). These data are
consistent with our observations in U2OS and SaOS2
cells.
Next, we examined the transcription of p53 target
genes using semiquantitative RT–PCR. We found that
levels of p21 and Puma transcripts were severely de-
creased in siBat3-transfected U2OS cells (Fig. 2C, left),
consistent with a defect in protein expression. Induction
of Hdm2 transcription was modestly impaired (Fig. 2C,
left). However, Bax transcription was not decreased in
the absence of Bat3 in this system (Fig. 2C).
To further show that the observed defects in p53 tran-
scriptional activity were indeed caused by specific deple-
tion of Bat3 protein and not by off-target effects, we
tested whether the phenotype could be rescued by a Bat3
mutant containing two silent point mutations within
the siBat3-1 recognition site (RNAi-B3). We first con-
firmed that ectopically expressed wild-type Bat3 (WT-B3)
was depleted by siBat3-1 transfection, whereas RNAi-
B3 was resistant (Fig. 2D). Then, we examined protein
levels of p53 and p53 target genes in Dox-treated U2OS
Figure 2. Impaired induction of p53 target
genes in Bat3-depleted cells. (A,B) Impaired
protein expression of p53 target genes. U2OS
and SaOS2 cells (A) and p53 wild-type and
p53-null HCT116 cells (B) were transfected
with siCNT or siBat3-1 RNA oligo-duplexes
and treated with Dox (0.4 µg/mL) for the in-
dicated times. Protein levels of p53, Hdm2,
p21, Bax, and Puma were determined by
Western blotting. (C) Impaired p53 target gene
transcription. U2OS and SaOS2 cells were
transfected and treated as in A, and levels of
Hdm2, p21, Bax, and Puma transcripts were
determined by semiquantitative RT–PCR
analysis. (GAPDH) Loading control. (D) Es-
tablishment of a Bat3 mutant resistant to
RNAi. U2OS cells subjected to Bat3 KD with
siBat3-1 RNA oligo-duplexes were transfected
with WT-B3 and RNAi-B3. Protein levels of
Bat3 were determined as in A. (E) Rescue of
the defective induction of p53 target genes by
introducing RNAi-B3. U2OS cells subjected
to Bat3 KD with siBat3-1 RNA oligo-duplexes
were transfected with WT-B3 and RNAi-B3.
The cells were then treated with Dox (0.4 µg/
mL) for the indicated times. Protein levels of
p53 and its targets were determined as in A.
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cells transfected with siBat3-1 plus either WT-B3 or
RNAi-B3. WT-B3 could not rescue defective induction
of p21 and Puma (Fig. 2E). In contrast, RNAi-B3 re-
stored the induction of p21 and Puma (Fig. 2E). Taken
together, these data suggest that Bat3 influences p53
transactivation and thus is essential for the induction of
a certain subset of p53 target genes.
Bat3 plays a role in DNA damage-induced p53
acetylation
In Dox-treated siBat3-transfected U2OS cells, p53 pro-
tein was stabilized (Fig. 2A,B) but p53 transactivation
was greatly reduced (Fig. 2C). We therefore speculated
that the Bat3 depletion might be affecting the post-trans-
lational modification of p53, since most such modifica-
tions are known to modulate p53 transcriptional activity
(Appella and Anderson 2001; Brooks and Gu 2003). We
first examined the phosphorylation of serine (Ser) resi-
dues 15, 20, and 392 of human p53, which are known to
be phosphorylated in response to DNA damage. U2OS
cells transfected with siCNT or siBat3 were treated with
Dox for 0, 4, or 8 h, and the phosphorylated forms of
Ser15, Ser20, and Ser392 were detected using specific
antibodies. Comparable levels of phosphorylation of all
three serine residues were detected in siCNT- and
siBat3-transfected cells (Fig. 3A), strongly suggesting
that Bat3 is not involved in p53 phosphorylation. Next,
we examined acetylation of p53. U2OS cells transfected
with siCNT or siBat3 were treated with Dox in the pres-
ence of the histone deacetylase inhibitor Tricostatin A
(TSA), which enhances the proportion of acetylated p53
(Sakaguchi et al. 1998). In siCNT-transfected cells,
acetylation of lysine (Lys) residues 320, 373, and 382 of
human p53 was readily observed at 4 h post-Dox treat-
ment and had increased by 8 h. In Bat3-depleted cells,
acetylation of these lysine residues was severely im-
paired (Fig. 3B).
Next, to exclude potential off-target effects of siBat3-1,
we examined whether the introduction of RNAi-B3
could restore Dox-induced p53 acetylation in the siBat3-
1-transfected cells. Introduction of RNAi-B3 restored
Dox-induced p53 acetylation (Fig. 3C, right), but WT-B3
did not (Fig. 3C, left). These data indicate that Bat3 is
necessary for the acetylation of p53 induced by DNA
damage.
Bat3 binds to p300 and enhances p300-mediated p53
acetylation
DNA damage-induced acetylation of p53 Lys320 in vitro
requires the cofactor PCAF, whereas the acetylation of
p53 Lys373/Lys382 depends on p300/CBP (Avantaggiati
et al. 1997; Gu and Roeder 1997; Lill et al. 1997; Sakagu-
chi et al. 1998). To test whether Bat3 interacts with these
cofactors, we cotransfected 293T cells with Myc-Bat3
plus Flag-p300, or Myc-Bat3 plus HA-PCAF. Immuno-
blot analysis revealed an interaction between Myc-Bat3
and Flag-p300 (Fig. 4A), but interaction between Myc-
Bat3 and HA-PCAF was not detectable (data not shown).
We then investigated whether Bat3 had a positive regu-
latory effect on p300–p53 interaction or p53 acetylation,
or both. We cotransfected H1299 cells with p53, Flag-
p300, and increasing amounts of Myc-Bat3. We then im-
munoprecipitated protein extracts with either anti-Flag
or anti-p53 antibodies. Immunoblotting with anti-p53 or
anti-Ac-p53 (Lys382) antibodies showed that the amount
of p53 associated with Flag-p300 increased with increas-
ing Myc-Bat3, as did the amount of acetylated p53 (Fig.
4B). When H1299 cells were subjected to Bat3 KD fol-
lowed by cotransfection with p53 and Flag-p300, both
the amount of p53 associated with Flag-p300 and p53
acetylation were dramatically decreased (Fig. 4C).
We next confirmed this finding for endogenous p53
and p300. Immunoprecipitation of protein extracts with
anti-Bat3 antibody and subsequent immunoblot analysis
with anti-p300 antibody revealed the interaction of the
Figure 3. Bat3 is necessary for DNA damage-induced p53
acetylation. (A) Normal p53 phosphorylation. U2OS cells were
transfected with siCNT or siBat3 RNA oligo-duplexes and
treated 48 h later with Dox (0.4 µg/mL). Protein samples were
prepared at the indicated time points post-Dox. Phosphoryla-
tion of p53 on Ser15, Ser20, and Ser392 (P-p53) was detected
using phospho-specific antibodies. (B) Impaired DNA damage-
induced p53 acetylation. U2OS cells were transfected and
treated as in A. Extracts were immunoprecipitated with anti-
p53 antibody (DO-1) and immunoblotted with antibodies spe-
cific for acetylated Lys320, Lys373, and Lys382 (Ac-p53). (C)
Rescue of the impaired DNA damage-induced p53 acetylation
by the RNAi-B3. U2OS cells were subjected to Bat3 KD and 24
h later they were transfected with WT-B3 and RNAi-B3. The
cells were then treated with Dox as in A. Protein levels of acety-
lated p53 were examined as in B. Data shown are representative
of four independent preparations.
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two endogenous proteins (Fig. 4D). Then, U2OS cells
were subjected to Bat3 KD followed by Dox treatment.
Immunoblotting of protein extracts at 0, 4, or 8 h post-
Dox using anti-p300 antibody showed that the amount
of p53 interacting with p300 was significantly reduced in
siBat3-transfected cells (Fig. 4E). These data indicate
that, in response to DNA damage, Bat3 positively regu-
lates p53–p300 interaction and the subsequent acetyla-
tion of p53.
Nuclear Bat3 is necessary for p53 acetylation
Because p300 is a nuclear protein and endogenous Bat3
in primary tissues has been reported to be in the cytosol
(Kislinger et al. 2006), we investigated whether nuclear
localization of Bat3 might be essential for its interaction
with p300 and its effect on p53 acetylation. We prepared
nuclear and cytosolic fractions from U2OS cells that had
been transfected with either siCNT or siBat3 and treated
with Dox. We found that p53 was stabilized in the pres-
ence of Dox, and that the majority of the p53 protein was
localized in the nucleus in both siCNT- and siBat3-trans-
fected cells (Fig. 5A). In untreated siCNT-transfected
cells (time 0 h), the majority of Bat3 protein was present
in the cytosol, and a smaller amount was detected in the
nucleus. However, after Dox treatment, Bat3 levels were
slightly increased in the nucleus (Fig. 5A, left). In con-
trast, in Bat3-depleted cells, Bat3 protein was markedly
reduced in the cytosol and undetectable in the nucleus
(Fig. 5A, right). In both siCNT- and siBat3-transfected
cells, p300 was detectable only in the nucleus and p300
protein levels did not change significantly after Dox
treatment (Fig. 5A). These data are consistent with the
idea that nuclear Bat3 is necessary for p300-mediated
p53 acetylation.
To confirm the importance of nuclear Bat3 for its posi-
tive regulatory effects on p300–p53 interaction and p53
acetylation, we have created two additional Bat3 mu-
tants: NLS-B3, which has two point mutations within
NLS, and NLS/RNAi-B3, which contains both NLS
and RNAi mutations. NLS-B3 localized only in the
cytosol (Fig. 5B), whereas WT-B3 localized mostly in the
nucleus (Fig. 5B). We then investigated whether WT-B3,
RNAi-B3, NLS-B3, and NLS/RNAi-B3 had a posi-
tive regulatory effect on p300–p53 interaction, p53 acety-
lation, or both. We transfected H1299 cells with siBat3-
1, followed by cotransfection of p53 and Flag-p300 plus
either Myc-WT-B3, Myc-RNAi-B3, Myc-NLS-B3, or
Myc-NLS/RNAi-B3. Myc-RNAi-B3 and Myc-NLS/
RNAi-B3 were resistant to siBat3-1 and expressed com-
parable levels of protein (Fig. 5C). We then immunopre-
cipitated protein extracts with either anti-Flag or anti-
p53 antibodies. Immunoblotting with anti-p53 or anti-
Ac-p53 (Lys382) antibodies showed that Myc-NLS/
RNAi-B3 failed to increase the amount of acetylated
Figure 4. Bat3 binds to p300 and enhances p300-me-
diated p53 acetylation. (A) Binding of Bat3 to p300.
293T cells were transfected with empty vector (−), Flag-
p300, Myc-Bat3, or Flag-p300 plus Myc-Bat3 as indi-
cated. Extracts prepared at 48 h post-transfection were
immunoprecipitated using beads conjugated to anti-
Flag antibody. The immunoprecipitated samples were
analyzed by Western blotting using anti-Myc antibody.
(B) Bat3-mediated enhancement of p53–p300 binding
and p53 acetylation. H1299 cells were transfected with
expression vectors for p53 (0.3 µg), p300-Flag (0.3 µg),
and Bat3-Myc (0.1, 0.2, 0.3, or 0.6 µg). The total amount
of DNA transfected was equalized by adding empty vec-
tor. At 48 h post-transfection, extracts were immuno-
precipitated as in A, followed by immunoblotting with
anti-p53 antibody (polyclonal). The extracts were also
immunoprecipitated with anti-p53 antibody (DO--
1), followed by immunoblotting with anti-acetylated
p53 (Lys382). (C) Suppression of p53–p300 binding and
p53 acetylation by Bat3 KD. H1299 cells were trans-
fected with control or Bat3-specific siRNA oligo-du-
plexes and cotransfected 24 h later with Flag-p300 (0.6
µg) and p53 (0.6 µg). After another 24 h, extracts were
immunoprecipitated to examine p53–p300 interaction
and p53 acetylation as in B. (D) Binding of endogenous
Bat3 and p300. Extract prepared from U2OS cells was
immunoprecipitated using anti-Bat3 antibody or con-
trol IgG. The immunoprecipitated samples were ana-
lyzed by Western blotting using anti-p300 antibody. (E) Reduced interaction of endogenous p53 and p300 following Bat3 KD. U2OS
cells were transfected with control or Bat3-specific siRNA oligo-duplexes and treated 48 h later with Dox (0.4 µg/mL) for the indicated
times. Extracts were immunoprecipitated with anti-p300 antibody followed by immunoblotting with anti-p53 antibody. For A–E,
“Input” represents the protein levels of the indicated molecules in the original extracts as determined by conventional Western
blotting.
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Figure 5. Nuclear localization of Bat3 is necessary for its activity. (A) Biochemical demonstration. U2OS cells transfected with
control or Bat3-specific siRNA oligo-duplexes were subjected to Dox (0.4 µg/mL) treatment. After 0, 4, or 8 h, cytosolic (C) and nuclear
(N) fractions were prepared from extracts. Protein levels of Bat3, p53, and p300 were determined by immunoblotting. (Lamin A)
Loading control for nuclear samples. (B) Establishment of a nuclear-localization-defective mutant of Bat3. U2OS cells transfected with
Myc-tagged WT-B3 and NLS-B3 were stained with anti-myc-FITC antibody. Nuclei were visualized using Hoechst 33258 (blue),
merge of myc and Hoechst 33258 staining. The point mutations introduced in NLS-B3 are indicated by asterisk. (C) Failure of the
enhancement of p53–p300 binding and p53 acetylation by NLS-B3. H1299 cells were transfected with control or Bat3-specific siRNA
oligo-duplexes and cotransfected 24 h later with WT-B3, RNAi-B3, NLS-B3, or NLS/RNAi-B3. At 48 h post-transfection, p53–
p300 binding and p53 acetylation were examined as in Figure 3. (D) Cellular demonstration. U2OS cells were transfected as in A and
treated with Dox for 0 or 8 h, at which times the cells were fixed, permeabilized, and stained with anti-Bat3 (panels a,e,i,m) or anti-p53
(DO-1; panels b,f,j,n) antibodies, followed by anti-rabbit IgG (green) or anti-mouse IgG (red). Nuclei were visualized using Hoechst
33258 (blue; panels c,g,k,o). (Panels d,h,l,p) Merge of Bat3 and Hoechst 33258 staining. Data shown are representative of four inde-
pendent preparations.
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p53 and p53 associating with p300 (Fig. 5C). In contrast,
Myc-RNAi-B3 enhanced p53–p300 association and p53
acetylation (Fig. 5C). These data provide further support
that nuclear Bat3 is required for its positive regulatory
effect on p300-mediated p53 acetylation.
To confirm these biochemical findings at the cellular
level, we investigated the subcellular localization of
p53 and Bat3 in U2OS cells. We transfected U2OS cells
with siCNT and siBat3, cultured them for 48 h, and
treated them with Dox for 8 h. The cells were then
fixed and stained with anti-p53 and anti-Bat3 antibodies,
as well as with Hoechst 33258 (to visualize nuclei). In
the absence of Dox, there was only trace staining of
p53 in both control and Bat3-depleted cells (Fig. 5D,
panels b,f). In siCNT-transfected cells, Bat3 was local-
ized in both the cytosol and nucleus (Fig. 5D, panel a).
However, in siBat3-transfected cells, Bat3 was unde-
tectable in the nucleus and stained only very weakly in
the cytosol (Fig. 5D, panel e). In the presence of Dox,
nuclear staining of Bat3 became stronger in siCNT-
transfected cells (Fig. 5D, panel i). In siBat3-transfected
cells, Bat3 was stained only in the cytosol even after
Dox treatment (Fig. 5D, panel m). Dox treatment
also induced p53, which accumulated in the nucleus in
both siCNT- and siBat3-transfected cells (Fig. 5D, panel
j,n). These observations are consistent with our bio-
chemical assays and further suggest that nuclear local-
ization of Bat3 is necessary for p300-mediated p53 acety-
lation.
Bat3 enhances p300-dependent p53 transcriptional
activity
We next examined the effect of Bat3 on the induction of
p53 target genes in a physiological setting. We used a
chromatin immunoprecipitation (ChIP) assay to deter-
mine whether p300, Bat3, acetylated p53, and nonacety-
lated p53 could bind to the promoters of the endogenous
p21, Puma, and Hdm2 genes in U2OS cells transfected
with siCNT or siBat3 and treated with Dox. Chromatin
was immunoprecipitated with anti-p53, anti-acetyl-p53
(Lys320/Lys380), anti-p300, or anti-Bat3 antibodies and
analyzed by PCR using primer pairs specific for the p53-
binding region of the p21, Puma, and Hdm2 promoters.
In Dox-treated siCNT-transfected cells, p53, acetylated
p53, p300, and Bat3 were recruited to the p53-binding
site in the p21, Puma, and Hdm2 promoters (Fig. 6, left).
In contrast, in Dox-treated Bat3-depleted cells, no anti-
body was able to precipitate the p53-binding region of
p21 and Puma (Fig. 6, right). Interestingly, p53 binding to
the Hdm2 promoter occurred in Dox-treated Bat3-de-
pleted cells, although to a lesser extent than in the con-
trol (Fig. 6, right). On the other hand, recruitment of
acetylated p53 or p300 to the Hdm2 promoter was se-
verely impaired in Bat3-depleted cells (Fig. 6, right).
These data are consistent with previous reports describ-
ing a functional and physical interaction between p53
acetylation and p300 recruitment that is necessary for
binding to p53-responsive elements (p53REs) in p53 tar-
get gene promoters (Avantaggiati et al. 1997; Lill et al.
1997; Barlev et al. 2001).
Bat3 deficiency impairs genotoxic stress responses in a
mouse model
Our in vitro data indicated that Bat3 was involved in
p53-mediated responses to genotoxic stress through the
regulation of p300-mediated p53 acetylation. To confirm
this finding in a mouse model, we took advantage of Bat3
knockout mice independently established in our labora-
tory (Supplementary Fig. 1). Although an initial report
indicated that Bat3-deficient mice are embryonic lethal
(Desmots et al. 2005), we found that the lethal pheno-
type can be partially rescued in the ICR genetic back-
ground (Supplementary Table 1).
Since puma deficiency is sufficient to suppress DNA
damage-induced apoptosis in thymocytes (Jeffers et al.
2003; Villunger et al. 2003), and the induction of Puma
was markedly impaired in our Bat3-depleted cells (Fig.
2A–C), we chose the thymus in which to investigate
whether Bat3 regulates apoptosis in vivo. Bat3+/+ and
Bat3−/− littermate mice were subjected to whole-body
-irradiation (-IR; 10 Gy) and the thymi were removed
at 0, 4, or 8 h post -IR. Each thymus was cut in half,
with one half used for histological analysis and the other
half used for biochemical analysis. Bat3−/− mice were
slightly smaller in size than their wild-type counterparts
(∼80% of wild-type weight at 6–8 wk of age). However,
there was no significant difference in total thymocyte
Figure 6. Bat3 is required for p53-mediated transcription. Im-
paired recruitment of p53 to the p21, Puma, and Hdm2 promot-
ers in the absence of Bat3. U2OS cells transfected with control
or Bat3-specific siRNA oligo-duplexes were treated with Dox
(0.4 µg/mL) for 8 h, and extracts were immunoprecipitated with
anti-p53, anti-acetylated p53 (Lys382 and 320), anti-p300, or
Bat3 antibodies. The p53-binding regions of the p21, Puma, and
Hdm2 promoters were amplified by PCR. Data shown are rep-
resentative of four independent preparations.
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number or in subpopulations of CD4/CD8-expressing
cells (Supplementary Fig. 2). Bat3 deficiency itself did
not induce spontaneous apoptosis or histological abnor-
malities in the thymus (Fig. 7A [panels a–c], B [panels
a–c]). In the wild type, low levels of apoptosis were de-
tected at 4 h post--IR that increased dramatically by 8 h
post--IR, consistent with previous reports (Lowe et al.
1993; Erster et al. 2004). Bat3−/− mice showed signifi-
cantly fewer apoptotic cells at 4 h post--IR than did the
wild type (Fig. 7A [panels e,f], B [panels e,f]), and the
impairment of -IR-induced apoptosis at 8 h post--IR
was much more prominent in Bat3-deficient thymus
than in the wild type (Fig. 7A [panels h,i], B [panels h,i]).
To confirm that this impaired apoptosis was due to a
defect in the p53 pathway, we examined the protein lev-
els of p53 and several p53 target genes in the thymi of
-IR-treated Bat3+/+ and Bat3−/− mice. Consistent with
our in vitro findings, p53 was stabilized in both wild-
type and Bat3-deficient thymi. However, the induction
of puma and p21 protein expression was greatly inhibited
in the absence of Bat3 (Fig. 7C). A much less striking
difference occurred in the induction of the bax and
mdm2 proteins. We also examined the level of activated
caspase-3, a conventional marker for apoptosis induc-
tion, to confirm our histological findings. Activated
caspase-3 was significantly reduced in Bat3-deficient
Figure 7. Impaired -IR-induced apoptosis in Bat3-deficient thymus. (A,B) Histological determination of impaired apoptosis. Six-
week-old Bat3+/+ (A) and Bat3−/− (B) littermate mice were left untreated or subjected to 10 Gy whole-body -IR. After 4 or 8 h, the
thymus was removed and cut in half. One half was fixed and subjected to histological analysis. The other half was used for biochemical
analysis, as shown in C. Serial sections of paraffin-embedded thymus were stained with H&E (A-,B, panels -a,d,g) and subjected to in
situ end-labeling (IEL) of fragmented DNA (A-,B, panels b,c,e,f,h,i). For each IEL preparation, two magnifications are shown (A-,B,
panels b,e,h: 10 × 10; A-,B, panels c,f,i: 10 × 25). Data shown are representative of three independent preparations. (C) Impaired
induction of p53 target genes and apoptosis. Half of the thymic lysates prepared in A were analyzed by Western blotting for protein
levels of the indicated proteins. (casp 3) Activated caspase-3. (D) Impaired induction of p53 target genes and p53 acetylation in
Dox-treated Bat3-deficient MEFs. Protein lysates prepared from Dox-treated Bat3+/+ and Bat3−/− MEFs were analyzed by Western
blotting for protein levels of the indicated proteins. Data shown are representative of three independent preparations.
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thymus. We also examined the protein levels of p53,
acetylated p53 Lys370 (corresponding to human Lys373),
and its target genes in Dox-treated Bat3+/+ and Bat3−/−
mouse embryonic fibroblasts (MEFs). Consistent with
our previous findings, the induction of puma and p21
protein expression as well as p53 acetylation was mark-
edly impaired in Bat3-deficient MEFs (Fig. 7D).
These findings in multiple tissues of the mouse model
further support our hypothesis that Bat3 is a critical
regulator of p53 function induced by genotoxic stress.
Discussion
In this study, we have defined the positive regulatory
role of Bat3 in DNA damage-induced p53 transactivation
and have started to unravel the molecular mechanisms
underlying its effects. Using biochemical and genetic ap-
proaches, we have shown that Bat3 is required for the
acetylation of p53 in response to DNA damage.
Bat3 is critical for p300-mediated acetylation of p53
It is well established that p53 is a node of genotoxic
stress signaling pathways. However, the precise mecha-
nism of action of p53 has been difficult to ascertain,
partly because of the complex and dynamic post-trans-
lational modifications undergone by p53. This study
demonstrates that Bat3 plays a fundamental role in p300-
mediated acetylation of p53 and ultimately regulates
DNA damage-induced stress responses in vitro and in
vivo (Figs. 1, 7). Bat3 can form a complex with p300 and
p53 (Fig. 4; Supplementary Fig. 4), and is recruited to
p53RE (Fig. 6). Thus, Bat3 may act as a cofactor to en-
hance p53 transactivation. In the absence of Bat3, p53 is
stabilized (Figs. 2, 7), phosphorylated (Fig. 3), localizes in
the nucleus (Fig. 5), and fails to become acetylated on
Lys320, Lys373, and Lys382 (Figs. 3, 7). Nonacetylated
p53 cannot bind to the p53REs in the promoters of p53
target genes such as p21 and Puma (Fig. 6), and, as a
consequence, p21 and Puma cannot be induced (Figs. 2,
7). In addition, binding of nuclear Bat3 to p300 positively
regulates p300–p53 binding and p53 acetylation (Figs. 4,
5). Furthermore, since Lys320 and Lys378/Lys382 acety-
lation are mediated by PCAF and p300/CBP in vitro, re-
spectively, our data suggest that p300 function may be
necessary for PCAF-mediated Lys320 acetylation in
vivo. Since p300 physically interacts with PCAF (Yang et
al. 1996), the recruitment of PCAF by p300 might be
required for its activity in vivo. The other possibility is
that conformational changes of the p53 CT by p300-me-
diated acetylation may allow PCAF to access Lys320.
Indeed, Lys320 acetylation was significantly impaired
when p300 was ablated in U2OS cells (Supplementary
Fig. 3). These lines of evidence further support our hy-
pothesis of an important Bat3–p300 connection.
Effects of CT modification on p53-inducible genes
To date, three major mechanisms have been proposed to
explain how modifications of the CT of p53 (including
phosphorylation, acetylation, CT-specific antibody
treatment, and deletion) regulate p53 activity. First, p53
CT modifications may enhance sequence-specific bind-
ing to p53REs. Second, p53 CT modifications may accel-
erate the recruitment of cofactors and alter chromatin
structure, thereby promoting transcription. Third, p53
CT modifications may stabilize the p53 protein by in-
hibiting Hdm2/Mdm2-mediated p53 ubiquitination.
There has been extended debate on how CT modifica-
tion might regulate sequence-specific DNA binding by
p53. In the allosteric model, the unmodified CT is a
negative regulator of the p53 DNA-binding domain and
maintains the inactive conformation until modification
occurs. The CT modification releases the negative effect
and allows active p53 to bind to DNA. Consistent with
this model, the acetylation of the p53 CT is induced by
numerous stress stimuli and significantly increases p53
transcriptional activity (Gu and Roeder 1997; Sakaguchi
et al. 1998; Ahn and Prives 2001; Luo et al. 2004). On the
other hand, several reports weigh against this model.
Since CT-deleted p53 (Cp53) is transcriptionally inac-
tive in an artificially reconstituted chromatin assay, the
p53 CT may be a positive regulator of p53 DNA binding
and transactivation (Espinosa and Emerson 2001). In ad-
dition, NMR analysis has shown that wild-type and
Cp53 are identical in conformation and that the CT
does not interact with other p53 domains (Ayed et al.
2001). In addition to this controversy, recent reports
have supported the importance of the p53 CT for p53
binding to nonlinear DNA (McKinney and Prives 2002;
Fojta et al. 2004; McKinney et al. 2004; Palecek et al.
2004). Finally, CT modification is necessary for efficient
promoter activation mediated by p53 (Liu et al. 2004;
McKinney et al. 2004). While our model cannot offer a
reconciliation of these discrepancies, we propose that
CT modifications may regulate both p53 DNA binding
and transactivation by modifying either p53 DNA bind-
ing or stability of p53–DNA complex, or both.
An inhibition of CT modification would not necessar-
ily have an “all or none” effect on the induction of p53
target genes. The sequence and structure of p53REs, as
well as the chromatin structure of the promoters of tar-
get genes, would also likely have a great influence. In our
model, levels of p21 and Puma induction were severely
impaired in the absence of Bat3, but Hdm2/Mdm2 in-
duction was only modestly affected (Figs. 2, 7). These
results suggest that at least two sets of p53 target genes
may exist: one (including genes such as Puma and p21)
that requires p53 acetylation for efficient induction, and
the other (including genes like Hdm2/Mdm2) that can be
induced to a limited extent by nonacetylated p53. Sev-
eral studies support this hypothesis. Firstly, Cp53 is
defective in its induction of p21 and apoptosis (Chen et
al. 1996). Secondly, CT modification is necessary for ef-
ficient p53 binding to the p21 promoter but not for bind-
ing to the Mdm2 promoter, presumably because these
two genes have structurally different p53REs (Kaku et al.
2001). Thirdly, Cp53 is much less efficient in binding
to the p21 promoter than to the Hdm2 promoter, in a
way that closely correlates with decreased induction of
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the target gene (McKinney et al. 2004). Taken together,
our findings and these reports suggest that a p53 protein
that cannot sustain CT acetylation will bind moderately
well to the Hdm2/Mdm2 promoter but hardly at all to
the Puma and p21 promoters.
It is also possible that p53 acetylation affects the re-
cruitment of cofactors like TRAP and p300/CBP. TRAP
is required for the formation of preinitiation complexes
(Ito et al. 1999), while p300/CBP has HATs activity re-
quired for the remodeling of chromatin structure (Avan-
taggiati et al. 1997; Barlev et al. 2001; Espinosa and
Emerson 2001). We have shown that, although p300 re-
cruitment to the p21 and Hdm2 promoters was impaired
in Bat3-depleted cells, a small amount of p53 binding to
the Hdm2 promoter did occur (Fig. 6). Thus, unacety-
lated p53 appears to be able to induce Hdm2. It also has
been reported that the patterns of p53-dependent histone
acetylation of the p21, Puma, and Hdm2 promoters dif-
fer in H3 and H4. The histone acetylation is increased in
both the p21 and Puma promoters in response to p53
activation, whereas there is only a small increase in H4
acetylation and no increase in H3 acetylation in the
Hdm2 promoter (Kaeser and Iggo 2004). Thus, the Hdm2
promoter may be activated without the acetylated p53-
mediated recruitment of cofactors and HATs and the his-
tone modifications that are essential for p21 and Puma
induction. A more precise correlation between p53 target
gene promoter sequences and patterns of p53 post-trans-
lational modifications is necessary to clarify this issue.
The last major mechanism proposes that acetylation
of the p53 CT influences p53 stability, since the CT ly-
sine residues that are targets for acetylation overlap
those ubiquitinated by Mdm2 (Rodriguez et al. 2000; Ito
et al. 2001). We have shown that impairment of p53
acetylation does not significantly affect the stability of
p53 in vitro or in vivo (Figs. 2, 7), implying that the
phosphorylation of the p53 N terminus that occurs in
response to DNA damage has a dominant inhibitory ef-
fect on Hdm2/Mdm2-mediated p53 degradation. Consis-
tent with this notion, a mutant form of p53 in which all
CT lysines are substituted with arginines shows virtu-
ally normal protein stability in a mouse model (Feng et
al. 2005; Krummel et al. 2005).
Bat3 modulates the function of apoptotic regulators
In cell-free extracts prepared from Xenopus eggs, the
Bat3 homolog, Scythe, is essential for Rpr-induced apop-
tosis in that immunodepletion of Scythe impedes Rpr-
induced caspase activation. Paradoxically, an excess re-
combinant Scythe in this system also suppresses Rpr-
induced apoptosis (Thress et al. 1999). To explain this, it
has been suggested that Scythe sequesters a proapoptotic
factor required for mitochondrial cytochrome c release
and that Scythe is necessary for the Hsp70-mediated
folding and activation of this putative factor. These data
are consistent with Scythe being a member of the BAG
family of proteins that modulate Hsp70-mediated pro-
tein folding. Indeed, although no mammalian homolog
of Rpr has been identified to date, Drosophila Rpr and its
associated proapoptotic molecules Hid and Grim can in-
duce apoptosis in mammalian cells (McCarthy and Dixit
1998; Goyal et al. 2000). In addition, viral proteins with
homology with Rpr have been shown to bind Bat3 and
trigger apoptosis (Colon-Ramos et al. 2003). Thus, func-
tional homologs of Rpr (Hid and Grim), a parallel signal-
ing pathway, or both may exist in mammalian systems.
We have shown that, in response to DNA damage, a
proapoptotic molecule, p53, is activated in a Bat3-depen-
dent manner and induces apoptosis. Although it is not
clear how our findings relate Scythe’s role in Rpr-in-
duced apoptosis, it may be that chaperone function of
Bat3/Scythe is important for its effects on p53. Nonethe-
less, we have clearly established that proapoptotic mol-
ecules exist as downstream targets of the Bat3 signaling
pathway in mammals. Moreover, an absence of Bat3 re-
sults in impaired apoptosis induction in vitro and in vivo
(Figs. 1, 7).
Bat3 may play a role in apoptosis induced by stimuli
other than DNA damage. Ricin, a type II ribosome-inac-
tivating protein, uses its RNA N-glycosidase activity to
inhibit protein biosynthesis (Wu et al. 2004). In addition,
ricin induces apoptosis by a mechanism that requires
caspase-3-mediated cleavage and release of the CT of
Bat3 (Wu et al. 2004), suggesting that the Bat3 CT retains
proapoptotic activity. This finding is quite intriguing be-
cause the 312 CT amino acids of Scythe (C312) also ex-
hibit an autonomous Rpr-independent ability to activate
caspases in the egg extract (Thress et al. 1998). However,
the precise role of the CT product in the regulation of
Bat3-mediated apoptosis is not clear because the cleav-
age of the CT appears to be stimulus-dependent. For in-
stance, staurosporine treatment does not result in the
release of the Bat3 CT (Manchen and Hubberstey 2001).
We also could not detect a significant amount of Bat3
cleavage product upon DNA damage (data not shown).
However, our results indicate that nuclear Bat3 is essen-
tial for the p300–p53 interaction (Fig. 4), and the Bat3/
Scythe CT is known to contain a NLS (Manchen and
Hubberstey 2001), which is required for nuclear localiza-
tion of Bat3 (Fig. 5). Thus, the modification of Bat3 CT by
caspase-3-mediated cleavage and other mechanisms may
have a regulatory effect on Bat3/Scythe function.
Most Bat3-deficient embryos exhibit impaired devel-
opment of multiple tissues due to a mixture of cell death
and proliferation defects (Desmots et al. 2005). This
complex phenotype clearly indicates that Bat3’s role in
vivo is not straightforward and that regulation of p53
may be only part of Bat3’s functions. Our findings,
coupled with previous reports, suggest that the contri-
bution of Bat3/Scythe to apoptotic regulation is highly
context-specific (Manchen and Hubberstey 2001; Kumar
et al. 2004; Wu et al. 2004; Desmots et al. 2005). For
instance, Bat3-deficient primary neuronal cells are resis-
tant to ER stress-induced apoptosis (Desmots et al.
2005), a form of cell death in which p53 acetylation may
not be a major factor. Thus, more precise biochemical
and genetic analyses to determine tissue-specific func-
tions of Bat3/Scythe will be necessary to fully under-
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stand the contribution of this molecule to the regulation
of apoptosis and cell proliferation.
In conclusion, our work demonstrates that Bat3 is nec-
essary for p300-mediated p53 acetylation, and functions
as a novel positive regulator of p53-mediated apoptosis
induced by genotoxic stress in vivo and in vitro. Since
dysregulation of the p300–p53 pathway has been ob-
served in multiple cancers (Goodman and Smolik 2000)
and a biallelic inactivating mutation of Bat3 has been
found in a colon cancer cell line (Ivanov et al. 2006), it
will be important to investigate whether mutations of
Bat3 are associated with the human diseases.
Materials and methods
Cell lines, transfections, and RNA interference (RNAi)
U2OS (p53 wild-type), SaOS2 (p53-null), and H1299 (p53-null)
cells were all originally obtained from the American Tissue
Culture Collection (ATCC). HCT116 cells (p53 wild-type and
p53-null) were a generous gift from Dr. Bert Vogelstein (Johns
Hopkins Kimmel Cancer Center, Baltimore, MD). Synthetic
siRNA oligo-duplexes for human Bat3 and human p300 were
purchased from Dharmacon and Santa Cruz Biotechnology, re-
spectively (sequences for siRNA oligo-duplexes are in the
Supplemental Material). Cells were cultured to 60% confluency
in Opti-MEM medium (Invitrogen) and transfected with siRNA
oligo-duplexes (final concentration, 40 nM) plus 3 µL of Lipo-
fectamine 2000 (Invitrogen). At 6 h post-transfection, the me-
dium was changed to complete medium. Transfected cells were
used for assays at 48 h post-transfection unless otherwise indi-
cated. All control samples were transfected with control siRNA
oligo-duplex (Dharmacon).
Apoptosis
U2OS cells transfected with Bat3-specific (siBat3-1 and siBat3-2)
or control siRNA oligo-duplexes were plated on six-well plates.
The cells were washed twice with prewarmed PBS (Mg- and
Ca-free) and treated with UV (0, 10, 30, or 100 mJ/cm2; Strata
Cross Linker) or staurosporine (0, 0.01, 0.03, or 1 µM; Sigma-
Aldrich). Treated cells were trypsinized after 16 h, washed in
PBS, and resuspended in 100 µL of 1× binding buffer (10 mM
HEPES, 140 mM NaCl, 2.5 mM CaCl2 at pH 7.4) containing
annexin V-FITC (final concentration, 25 µg/mL; Invitrogen) plus
propidium iodide (PI; final concentration, 10 µg/mL; Sigma-Al-
drich). Samples were incubated for 15 min at room temperature
with gentle agitation in the dark. An additional 300 µL of 1×
binding buffer were added to each sample prior to flow cytomet-
ric analysis using a FACScalibur (Becton Dickinson) as previ-
ously described (Okada et al. 2002). Data were analyzed using
CellQuest software.
Antibody production
For production of anti-human Bat3 antibody (Ab), human Bat3
DNA was subcloned into the pFastBac-HT vector (Invitrogen).
The 6× His-tagged Bat3 fusion protein was expressed in Spodop-
tera frugiperda Sf-9 cells using the BAC-TO BAC Baculovirus
Expression System according to the manufacturer’s instructions
(Invitrogen) and purified over a Ni-NTA column (Qiagen).
Polyclonal anti-mouse Bat3 Ab was generated by a custom
antiserum production service (SigmaGenosys) using a 6× His-
tagged recombinant protein corresponding to amino acids 1–160
of mouse Bat3. The bacterially produced recombinant protein
was purified using a Ni-NTA column (Qiagen) according to the
manufacturer’s instructions. Rabbits were immunized with the
recombinant proteins.
Western blot analysis
Protein samples were prepared in lysis buffer (0.1% SDS, 0.1%
DOC, 1% Triton X-100, 20 mM Tris-HCl at pH 7.5, 150 mM
NaCl, 1 mM EDTA, 10 mM NaF, 1 mM NaVO4, protease in-
hibitor cocktail [Roche Diagnostics]) and 1 µM tricostatin A
(Sigma-Aldrich), and 20 µg were immunoblotted according to
standard procedures. Abs recognizing the following proteins
were used in this study: p53 (DO-1), p300 (N-15, C-20), MDM2
(C-18), Bax (N-20), and Lamin A, all from SantaCruz Biotech-
nology; phospho-p53 (Ser15, Ser20, and Ser392) and p53 poly-
clonal Ab, both from Cell Signaling Technology; acetylated p53
(Lys320 and Lys373) from Upstate Biotechnology; acetylated
p53 (Lys382) from Cell Signaling; PUMA from ProSci; p21 and
active caspase-3 from BD Pharmingen; Flag (M2) and actin, both
from Sigma. Subcellular fractionation was performed as previ-
ously described (Andrews and Faller 1991).
Immunofluorescent microscopy
Cells were fixed in cold methanol for 15 min and blocked in
2.0% BSA, 0.2% Triton X-100, and PBS for 1 h. Slides were
incubated with mouse anti-p53 and rabbit anti-Bat3 as primary
antibodies followed by AlexaFluor488 goat anti-rabbit IgG and
AlexaFluor594 goat anti-mouse IgG (Molecular Probes) as sec-
ondary antibodies. Hoechst 33258 (Molecular Probes) was used
to stain DNA. Images were acquired on a Zeiss LSM510 confo-
cal microscope (Jena) using a 63×/1.2 NA water immersion ob-
jective. The three fluorophores DAPI, Alexa 488, and Alexa 594
were imaged sequentially using 351-, 488-, and 543-nm laser
excitation and appropriate band-pass emission filters.
Imunoprecipitations
293T cells were transfected with empty vector (pcDNA3; Invit-
rogen), Flag-300 pcDNA3, or Myc-Bat3 pcDNA3. Cells were
lysed in lysis buffer (50 mM Tris HCl, 150 mM NaCl, 1% NP40)
supplemented with protease inhibitor cocktail (Roche Diagnos-
tics) for 30 min on ice and cleared by centrifugation. Extracts
were incubated with the appropriate antibodies for 16 h at 4°C
with rotation and incubated for an additional 2–3 h with protein
A/G agarose beads (SantaCruz Biotechnology). In some experi-
ments, anti-Myc agarose beads (SantaCruz Biotechnology) were
used to pull down Myc-tagged proteins. The samples were frac-
tionated by SDS-PAGE and subjected to immunoblotting as de-
scribed above.
RT–PCR analysis
Total RNA was extracted from cells using TRIzol (Life Tech-
nologies). First-strand DNA was synthesized using the Super-
Script First-Strand Synthesis System (Invitrogen) followed by
PCR specific for the target genes. Primer sequences are in the
Supplemental Material.
ChIP
Cells were cross-linked with 1% (v/v) formaldehyde, and ChIP
was performed according to the manufacturer’s protocol (CHIP-
IT Enzymatic Kit; Active Motif). The primers for p21 and Hdm2
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have been previously described (McKinney et al. 2004; Wei et al.
2005). Primer sequences are in the Supplemental Material.
Bat3 mutants
To obtain a human Bat3 mutant resistant to RNAi by siBat3-1
(RNAi-B3), two silent point mutations were introduced within
the siBat3-1 recognition site using the oligonucleotide 5-GGA
CAAATTTGGAATTTCTCCAA-3. To create a NLS mutant
(NLS-B3), we introduced two point mutations within the NLS
consensus sequence as previously reported (Manchen and Hub-
berstey 2001). We also established a mutant containing both
mutations, NLS/RNAi-B3. The mutations were introduced
by the QuikChange Mutagenesis Kit (Stratagene) according to
the manufacturer’s protocol. All of the mutations were verified
by sequencing.
Histology
To analyze apoptosis in the thymus in vivo, mice (6- to 8-wk-
old) were irradiated with 10 Gy from a 137Cs source (Gammacell
40) at a dose of 1.0 Gy/min. The thymus was removed either
immediately (0 h) or at 4 or 8 h post--IR and fixed in 10%
buffered formalin overnight at 4°C. Tissue samples were em-
bedded in wax according to standard procedures and sectioned
at a thickness of 4 µm. Apoptosis in tissue sections was ana-
lyzed by in situ end-labeling of fragmented DNA as previously
described (Wijsman et al. 1993). Hematoxylin-eosin (H&E)
staining was performed according to a standard protocol.
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